

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
2 August 2007 (02.08.2007)

PCT

(10) International Publication Number
WO 2007/085084 A1

(51) International Patent Classification:

C12N 15/62 (2006.01) **C07K 16/18** (2006.01)
A61K 38/18 (2006.01) **C07K 19/00** (2006.01)
A61K 47/42 (2006.01) **C12N 15/13** (2006.01)
A61K 47/48 (2006.01) **C12N 15/18** (2006.01)
A61P 7/00 (2006.01) **C12P 21/02** (2006.01)
C07K 14/505 (2006.01)

(21) International Application Number:

PCT/CA2007/000107

(22) International Filing Date: 25 January 2007 (25.01.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

11/340,661 27 January 2006 (27.01.2006) US

(71) Applicant (for all designated States except US): **NO-VAGEN HOLDING CORPORATION**; PO Box 484
GT, Strathvale House, North Church Street, George Town,
Grand Cayman (KY).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **WANG, Haitao**
[CN/CA]; 22 - 3240 East 58th Avenue, Vancouver, British
Columbia V5S 3T2 (CA). **DU, Yong** [CN/CA]; 51 - 3260
East 58th Avenue, Vancouver, British Columbia V5S
3T2 (CA). **ZHANG, Rui** [CN/CA]; 22 - 3240 East 58th
Avenue, Vancouver, British Columbia V5S 3T2 (CA). **XU,
Jing** [CN/CA]; 131 - 3280 East 58th Avenue, Vancouver,
British Columbia V5S 3T2 (CA). **LIU, Longbin** [CA/CA];
1528 Errigal Place, West Vancouver, British Columbia
V7S 3H1 (CA).

(74) Agents: **BAILEY, Thomas, W.** et al.; Oyen Wiggs Green
& Mutala LLP, 480 - The Station, 601 West Cordova Street,
Vancouver, British Columbia V6B 1G1 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS,
LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,

[Continued on next page]

(54) Title: RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED
ERYTHROPOIETIC ACTIVITY IN VIVO

1B
ATGGGGGTGCACGAATGCTGCTGGCTGGCTGTGCTCTCTGCTCTGCTGCTGCTCTCT 60
M G V H E C P A W L W L L L S L L S L P
CTGGGCTCCAGTCTGGGCGGCCACCGCTCATCTGTGACAGCGAGTCTCTGGAG 120
L G L P V L G A P P R L I C D S R V L E
AGGTACCTCTGGAGGCCAAGGAGGCGAGAATATCAGCAGCGGCTGTGCTGAACACTGC 180
R Y L L E A K E A E N I T T G C A E H C
AGCTTGAATGAGAATATCACTGCCAGACACCAAGTTAATTCTATGCTGGAAGAGG 240
S L N E N J T V P D T K V N F Y A W K R
ATGGAGGTCGGGACGAGGCGGTAGAACTCTGGCAGGCGCTGGGCTGCTGCTGGAAGCT 300
M E V G Q Q A V E V W Q G L A L L S E A
GTCTGCGGGGCGAGGCTCTGTGTGCTCACTCTCCAGCGCTGGGCTGCTGCTGGAAGCT 360
V L R G Q A L L V N S S Q P W E P L Q L
CATGTGGAAGGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
H V D K A V S G L R S L T T L L R A L R
GCCAGAAGGAGCACTCTCCCTCCAGATGCGGCTCAGCTGCTCCACTCCGAACAACT 480
A Q K E A I S P P D A A S A A P L R T I
ACTGCTGACACTTCCGCAAACTCTCCGAGTCTACTCAATTTCCTCCGGGGAAGCTG 540
T A D T F R K L F R V Y S N F L R G K L
AAGCTGTACACAGGAGGCTGACAGGACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 600
K L Y T G E A C R T G D R V E P K S G D
AAACTAGTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 660
K T S T G P P G P A P E L L G G P S V F
CTCTCCGCAAAACCAAGGACACCTCATGATCTCCGAGCAGCTGAGGTCACATGC 720
L F P P K P K D T L M I S R T P E V T C
CTGGTGGTGAAGTGAAGACCAAGACCTGAGGTCAAGTTCAACTGGTACGTGGAAGGC 780
V V V D V S H E D P E V K F N W Y V D G
GTGGAGGTGCAATATGCCAAGACAAAGCCGCGGGAGGAGGAGGAGGAGGAGGAGGAGG 840
V E V H N A K T K P R E E Q Y N S T Y R
GTGGTCAAGCTCTCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900
V V S V L T V L H Q D W L N G K E Y K C
AAGGTCTCAACAAAGCCCTCCAGCCCATCGAGAAACCACTCCGAGGAGGAGGAGGAGG 960
K V S N K A L P A P I E K T I S K A K G
CAGCCCGGAGAACCAAGGTGTACACCTGCGCCCATCCGCGGATGAGCTGACCAAGAGT 1020
Q P R E P Q V Y T L P P S R D E L T K N
CAGGTCAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1080
Q V S L T C L V K G F Y P S D I A V E W
GAGAGCAATGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1140
E S N G Q P E N N Y K T T P P V L D S D
GGCCCTCTTCTCTACAGCAAGCTCAGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1200
G P F F L Y S K L T V D K S R W Q Q G N
GTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
V F S C S V M H E A L H N H Y T Q K S L
TCCGTGCTCCGGTAAATAA 1320
S L S P G K *

(57) Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.



RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.